CTS

CTS EVENTIM: Proposed sale of Vivendi’s festival and international ticketing activities to CTS EVENTIM

Retrieved on: 
Wednesday, April 10, 2024
Culture, Growth, Sale, Acquisition, Executive Committee, See Tickets, Music, CTS, Film industry

Paris/Munich, 2 April 2024 – CTS EVENTIM, a leading international provider of ticketing services and live entertainment, and Vivendi, a global leader in culture, entertainment, media and communications, have signed a put option agreement on the sale of Vivendi’s festival and international ticketing activities.

Key Points: 
  • Paris/Munich, 2 April 2024 – CTS EVENTIM, a leading international provider of ticketing services and live entertainment, and Vivendi, a global leader in culture, entertainment, media and communications, have signed a put option agreement on the sale of Vivendi’s festival and international ticketing activities.
  • Vivendi’s ticketing and festival activities that CTS EVENTIM is set to acquire collectively produced €137 million in revenues in 2023.
  • With CTS EVENTIM, Vivendi has found a fitting new home for its festival and international ticketing activities.
  • CTS EVENTIM has been in the festival business for many years, and is committed to continually expanding this vibrant segment.

EQS-News: CTS EVENTIM celebrates 18th record year since its IPO

Retrieved on: 
Wednesday, April 10, 2024
EUR, Annual report, Growth, Supervisory board, AG, Partnership, Sale, IPO, LANXESS, Creativity, INC, Exhibition, Live, CTS Eventim, Artisan Entertainment, Government, CTS

EQS-News: CTS Eventim AG & Co. KGaA

Key Points: 
  • EQS-News: CTS Eventim AG & Co. KGaA
    The issuer is solely responsible for the content of this announcement.
  • Annual revenue surpasses the EUR 2 billion mark for the first time and rises to EUR 2.359 billion (+22%), the 18th record figure since the IPO in 2000.
  • Klaus-Peter Schulenberg, CEO of CTS EVENTIM: ”Live entertainment is once again driving the arts and creative sectors.
  • Klaus-Peter Schulenberg, CEO of CTS EVENTIM: ”These excellent results are proof that live entertainment is once again driving the arts and creative sectors.

Clearmind Medicine CEO Issues Letter to Shareholders

Retrieved on: 
Tuesday, April 9, 2024
Data monitoring committee, Depression, Obesity, Mevalonate pathway, Psychiatry, Dyskinesia, Addiction, Safety, Binge drinking, Data, DSM-IV codes, Research, MEAI, Clinical trial, Johns Hopkins University, Phase, Patent, Therapy, Ministry, FDA, Impulsivity, CTS, IRB, Pharmaceutical industry

Recently, our efforts reached a key inflection point as the Israeli Ministry of Health approved our Phase I/IIa clinical trial for CMND-100 for AUD.

Key Points: 
  • Recently, our efforts reached a key inflection point as the Israeli Ministry of Health approved our Phase I/IIa clinical trial for CMND-100 for AUD.
  • CMND-100, a pioneering MEAI-based (5-methoxy-2-aminoindane) formula, has exhibited encouraging results in pre-clinical studies.
  • Notably, it has shown the ability to disrupt the destructive cycle of binge drinking without inducing hallucinations—a common concern with existing treatments.
  • The journey ahead is filled with potential, and we eagerly anticipate sharing impactful updates with our shareholders."

World Orphan Drug Alliance Expands to Japan & South Korea and the African Subcontinent

Retrieved on: 
Monday, April 8, 2024
Disease, Science, Greater, Patient, WODA, Therapy, Ecosystem, CIS, Pharma, CTS, Pharmaceutical industry

Japan, South Korea, and the African subcontinent are now covered by the Alliance.

Key Points: 
  • Japan, South Korea, and the African subcontinent are now covered by the Alliance.
  • TOKYO and ZUG, Switzerland, April 08, 2024 (GLOBE NEWSWIRE) -- The World Orphan Drug Alliance (WODA), a global alliance of commercial distributors dedicated to providing access to treatments for rare diseases and specialty medicines in complex markets around the world, has expanded its reach to include Japan and South Korea, as well as the African subcontinent.
  • “Adding Nxera Pharma, formerly Sosei Heptares, in Japan and South Korea serves to round out our Asian offering.
  • People with rare or orphan diseases in Japan and South Korea deserve better access to effective, life-changing medicines.

Blue Biofuels Makes First Cellulosic Ethanol

Retrieved on: 
Tuesday, March 26, 2024
Ethanol, Aviation biofuel, PALM, Biofuel, SAF, BEACH, Biomass, OTCQB, CTS, Renewable energy

About Blue Biofuels, Inc.Blue Biofuels is based in Florida and has the goal to produce biofuels through its developed Cellulose-to-Sugar (CTS) technology. CTS is a sustainable, and renewable green energy system with the potential to achieve a near-zero carbon footprint. The CTS process can convert virtually any plant material – grasses, forestry products, and agricultural waste such as sugarcane bagasse and wheat straw -- into sugars and lignin. Sugars are subsequently processed into biofuels, such as ethanol and sustainable aviation fuel, and lignin may be further processed into a variety of products. The CTS process is a patented and proprietary technology wholly owned by Blue Biofuels.

Key Points: 
  • PALM BEACH GARDENS, FL, March 26, 2024 (GLOBE NEWSWIRE) -- Blue Biofuels, Inc. (OTCQB: BIOF).
  • Blue Biofuels Inc. ("BIOF") continues to make substantial strides in advancing its Cellulose-to-Sugar (CTS) technology towards commercial scale.
  • The company has achieved a significant milestone by successfully producing its first batch of cellulosic ethanol, utilizing the cellulosic sugars created from biomass on its CTS pilot line.
  • BIOF is evaluating prospective locations in Florida capable of accommodating both SAF and cellulosic ethanol production facilities.

CTS Engines Secures Approval for CF6-80E1 Engine Test Cell Correlation, Sole Facility in North America Catering to Operators

Retrieved on: 
Monday, April 8, 2024
Transportation, Aerospace, Manufacturing, Travel, Other Transport, Air, Transport, Military, Other Defense, Defense, Engineering, Original equipment manufacturer, Engine, MRO, TCS, Wind, OEM, Atmosphere, Multimedia, CF6, CTS, Medical imaging

This milestone achievement underscores CTS Engines' long-term commitment to the CF6 engine line and offers operators another option to fulfill their engine requirements.

Key Points: 
  • This milestone achievement underscores CTS Engines' long-term commitment to the CF6 engine line and offers operators another option to fulfill their engine requirements.
  • View the full release here: https://www.businesswire.com/news/home/20240408369861/en/
    CTS Engines Secures Approval for CF6-80E1 Engine Test Cell Correlation (Photo: Business Wire)
    The CF6-80E1 test cell correlation was approved by the OEM using our state-of-the-art Turbine Control Structure (TCS).
  • With this approval, CTS Engines will stand as the exclusive MRO in North America providing full-scale CF6-80E1 overhaul and testing services for operators."
  • The approval of the test cell correlation for the CF6-80E1 engine reinforces CTS Engines' position as a trusted partner in the aerospace industry for mature turbofan engines.

Converge Technology Solutions Achieves Cisco Gold Provider Status

Retrieved on: 
Thursday, April 4, 2024
Cloud, Managed services, QC, Converge, TSX, Cisco, Gold, Unified communications, Meraki, CTS, Network equipment provider

TORONTO and GATINEAU, QC, April 4, 2024 /PRNewswire/ - Converge Technology Solutions Corp. ("Converge" or "the Company") (TSX: CTS) is pleased to announce it has achieved Cisco Gold Provider partner status within special significance to Managed Services, including three powered services designations.

Key Points: 
  • TORONTO and GATINEAU, QC, April 4, 2024 /PRNewswire/ - Converge Technology Solutions Corp. ("Converge" or "the Company") (TSX: CTS) is pleased to announce it has achieved Cisco Gold Provider partner status within special significance to Managed Services, including three powered services designations.
  • Converge was specifically recognized by Cisco for achieving Gold designation in the powered services areas of Cloud Calling, Cloud Managed Security, and Meraki SD-WAN.
  • Additionally, Converge's Gold Provider status will translate into significant advantages for customers, with access to cutting-edge network solutions, the latest technologies, and comprehensive support.
  • "Converge is thrilled to be named a Cisco Gold Provider," stated Greg Berard, Converge Chief Executive Officer.

Converge Technology Solutions Awarded Broadcom's North America Fastest Growth Cybersecurity Partner of the Year and VMware by Broadcom's Americas Technical Enablement Partner of the Year

Retrieved on: 
Tuesday, April 2, 2024
Organization, Growth, Partnership, Broadcom Inc., Converge, VMware, TSX, Computer security, CTS, Video game

TORONTO and GATINEAU, QC, April 2, 2024 /PRNewswire/ - Converge Technology Solutions Corp. ("Converge" or "the Company") (TSX: CTS) is pleased to announce it has been named Broadcom Software's 2023 North America Fastest Growth Cybersecurity Partner of the Year and VMware by Broadcom's 2023 Americas Technical Enablement Partner of the Year at this year's Broadcom Partner Awards.

Key Points: 
  • TORONTO and GATINEAU, QC, April 2, 2024 /PRNewswire/ - Converge Technology Solutions Corp. ("Converge" or "the Company") (TSX: CTS) is pleased to announce it has been named Broadcom Software's 2023 North America Fastest Growth Cybersecurity Partner of the Year and VMware by Broadcom's 2023 Americas Technical Enablement Partner of the Year at this year's Broadcom Partner Awards.
  • The Broadcom Partner Awards and newly established VMware by Broadcom Partner Awards honor key partners for their outstanding achievements and impact over the last year.
  • Converge was crowned the Fastest Growth Partner of the Year for Cybersecurity based on the above factors, as well as the Company's year-over-year growth, while the Americas Technical Enablement Partner of the Year was awarded based on Converge's technical skills and ability to assist clients in deploying and using VMware by Broadcom technology.
  • "Converge is honored to be named Broadcom's Fastest Growth Cybersecurity Partner of the Year and VMware by Broadcom's Americas Technical Enablement Partner of the Year," stated Greg Berard, Converge Chief Executive Officer.

C-Path Launches Clinical Trial Simulator for Duchenne Muscular Dystrophy Research

Retrieved on: 
Thursday, March 28, 2024
Research, Vital capacity, Atrophy, Disease, Data analysis, Letter, Pharming, Female, European Medicines Agency, Duchenne muscular dystrophy, Clinical trial, Drug development, FCP, FDA, DMD, CTS, Food, Pharmaceutical industry

This pioneering Drug Development Tool is set to positively impact the medical research community by significantly optimizing clinical trial design.

Key Points: 
  • This pioneering Drug Development Tool is set to positively impact the medical research community by significantly optimizing clinical trial design.
  • This Clinical Trial Simulator will positively impact DMD research by significantly optimizing clinical trial design.
  • "The launch of the DMD Clinical Trial Simulator represents a significant step forward in our fight against Duchenne muscular dystrophy," said Ramona Belfiore-Oshan, Ph.D., Executive Director for D-RSC.
  • Granting access to the D-RSC Clinical Trial Simulator through RDCA-DAP creates a unique opportunity for innovative trial designs in DMD," said Alexandre Bétourné, Pharm.D., Ph.D., Executive Director, RDCA-DAP.

CTS Wins OnGo Alliance Award for CBRS-based Excellence in OnGo Device Innovation

Retrieved on: 
Wednesday, March 27, 2024
Construction, LTE, CBRS, Internet, Videotelephony, Citizens Broadband Radio Service, Radio, Internet access, Host, Workplace, CTS, Mobile phone

MARLBOROUGH, Mass., March 27, 2024 /PRNewswire/ -- Communication Technology Services (CTS), an in-building and campus connectivity solution provider, has won the 2023 Excellence in OnGo Device Innovation from the OnGo Alliance for its SiteNet™ construction site communications service. This achievement validates CTS's innovative approach to continuing to deploy private cellular solutions. It is the second year in a row that CTS has won an OnGo Award, after winning the 2022 OnGo Neutral Host Architecture/Solution Award for its Multi-Operator Core Network (MOCN) Neutral Host solution for a leading healthcare provider.

Key Points: 
  • MARLBOROUGH, Mass., March 27, 2024 /PRNewswire/ -- Communication Technology Services (CTS), an in-building and campus connectivity solution provider, has won the 2023 Excellence in OnGo Device Innovation from the OnGo Alliance for its SiteNet™ construction site communications service.
  • It is the second year in a row that CTS has won an OnGo Award, after winning the 2022 OnGo Neutral Host Architecture/Solution Award for its Multi-Operator Core Network (MOCN) Neutral Host solution for a leading healthcare provider.
  • CTS created the SiteNet™ jobsite communications system as a powerful new way of enabling wireless Internet connectivity throughout construction sites.
  • The 2023 OnGo Awards ( ongoawards.org ) were judged by a panel of industry analysts with distinct expertise in the OnGo market.